In collaboration with the National Cancer Institute, investigators in the Tucker Gosnell Center for Gastrointestinal Cancers are conducting innovative protocols in:

• Phase II study of capecitabine, cxalplatin, and tarceva in metastatic colon cancer
• Phase II study of capecitabine and tarceva in metastatic pancreatic cancer
• Phase I/II study of bevacizumab, 5-FU, and external beam radiation therapy in rectal cancer
• Phase II study of epirubicin and thalidomide in hepatocellular carcinoma
• Phase I study of S-1 in upper gastrointestinal malignancies

Read more on clinical research in gastrointestinal cancers.